<DOC>
	<DOC>NCT01488578</DOC>
	<brief_summary>The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.</brief_summary>
	<brief_title>Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)</brief_title>
	<detailed_description>All the subjects whom an investigator prescribes the first Detrusitol Capsule should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.</detailed_description>
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Tolterodine Tartrate</mesh_term>
	<criteria>Male or female subjects intend to treat their overactive bladder who are prescribed Detrusitol Capsule by their physicians. Subjects who have been prescribed Detrusitol Capsule before.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Overactive Bladder</keyword>
	<keyword>Japanese</keyword>
	<keyword>Tolterodine</keyword>
	<keyword>Detrusitol</keyword>
	<keyword>Detrol</keyword>
	<keyword>Postmarketing commitment plan.</keyword>
</DOC>